Saturday, April 27, 2024

No Result

View All Result

Media

No Result

View All Result

Health

We should change how we evaluate cancer drugs: Nigel Rawson, Chak Balijepalli and David Stewart in the Financial Post

April 16, 2024

Nigel Rawson

Inside Policy

Waiting for new drugs for rare disorders in Canada, part 4 – government drug plan listing: Nigel Rawson and John Adams for Inside Policy

August 2, 2023

Inside Policy

Waiting for new drugs for rare disorders in Canada – part 3, price negotiation: Nigel Rawson and John Adams for Inside Policy

July 26, 2023

Inside Policy

Waiting for new drugs for rare disorders in Canada – part 2, health technology assessment: Nigel Rawson and John Adams for Inside Policy

July 19, 2023

Inside Policy

Waiting for new drugs for rare disorders in Canada – part 1, regulatory approval: Nigel Rawson and John Adams for Inside Policy

July 12, 2023

Time for the PMPRB to go: Nigel Rawson and Brett Skinner in the Hill Times

Columns

The PMPRB has outlived its usefulness: Nigel Rawson in the Hill Times

June 28, 2023

The Patented Medicine Prices Review Board is selling Canadians a lemon: Nigel Rawson for Inside Policy

Columns

Lower drug prices are a good thing. Canada’s approach to achieving them was not: Nigel Rawson in the Globe and Mail

March 17, 2023

The U.S. outsources control of drug prices to Canada: weird! Richard Owens in the Financial Post

Columns

The drug prices review board was once a solution. It’s now a problem: Nigel Rawson and John Adams in the Financial Post

March 1, 2023

Columns

For drug access, Canadians with rare disorders are 40 years behind Americans: Nigel Rawson and John Adams in the Financial Post

January 24, 2023

Can we afford National Pharmacare and do people want it? Jeffrey Simpson for Inside Policy

Columns

PMPRB continues plan to drive down drug prices as patients suffer: Nigel Rawson and John Adams for Inside Policy

November 23, 2022

Build health care back better: Philip Cross in the Financial Post

Columns

Suffer from a rare disorder in Canada? Good luck: Nigel Rawson and John Adams in the Financial Post

November 2, 2022

Columns

Ongoing uncertainty about prices will deter new drug launches in Canada: Nigel Rawson and Brett Skinner in the Hill Times

September 8, 2022

Health

Ottawa should reset its relationship with drug developers to improve patient health: Rawson and Adams for Inside Policy

May 2, 2022

Page 2 of 3 Prev 1 2 3 Next

Newsletter Signup

Email Address *

First Name *

Last Name *

*Required Fields

Follow us on

Macdonald-Laurier Institute

Support Us

Support the Macdonald-Laurier Institute to help ensure that Canada is one of the best governed countries in the world. Click below to learn more or become a sponsor.

Support Us

No Result

View All Result

We should change how we evaluate cancer drugs: Nigel Rawson, Chak Balijepalli and David Stewart in the Financial Post

Nigel Rawson

Waiting for new drugs for rare disorders in Canada, part 4 – government drug plan listing: Nigel Rawson and John Adams for Inside Policy

Waiting for new drugs for rare disorders in Canada – part 3, price negotiation: Nigel Rawson and John Adams for Inside Policy

Waiting for new drugs for rare disorders in Canada – part 2, health technology assessment: Nigel Rawson and John Adams for Inside Policy

Waiting for new drugs for rare disorders in Canada – part 1, regulatory approval: Nigel Rawson and John Adams for Inside Policy

The PMPRB has outlived its usefulness: Nigel Rawson in the Hill Times

Lower drug prices are a good thing. Canada’s approach to achieving them was not: Nigel Rawson in the Globe and Mail

The drug prices review board was once a solution. It’s now a problem: Nigel Rawson and John Adams in the Financial Post

For drug access, Canadians with rare disorders are 40 years behind Americans: Nigel Rawson and John Adams in the Financial Post

PMPRB continues plan to drive down drug prices as patients suffer: Nigel Rawson and John Adams for Inside Policy

Suffer from a rare disorder in Canada? Good luck: Nigel Rawson and John Adams in the Financial Post

Ongoing uncertainty about prices will deter new drug launches in Canada: Nigel Rawson and Brett Skinner in the Hill Times

Ottawa should reset its relationship with drug developers to improve patient health: Rawson and Adams for Inside Policy

Top News

The Macdonald-Laurier Institute welcomes Tony Abbott as a Visiting Senior Fellow

Soak-the-rich may be fun but it doesn’t pay: Jack Mintz in the Financial Post

Trudeau and Ford double down on wasteful corporate welfare with yet another EV deal: Aaron Wudrick in the Hub

Multimedia

Hon. Tony Abbott in conversation with Brian Lee Crowley

Billionaire Igor Makarov wants off Canada’s Russia sanctions list: Marcus Kolga on Global News

Exploring Innovation in Canadian Health Care

Time for an intervention – an urgent call to end “gender-affirming” treatments for children: J. Edward Les for Inside Policy

The Governor General deserves better, but we deserve impartiality: Philippe Lagassé for Inside Policy

Conservatives can reject destructive left-wing policies and still take climate change seriously: Brian Lee Crowley in the National Post

Success assured? Appraising the Canadian-led Enhanced Forward Presence battlegroup in Latvia

Widespread shortages, skyrocketing costs: the growing calamity that is government-controlled child care

Newsletter Signup

Follow us on

Macdonald-Laurier Institute

Support Us